| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 49.72 | 0.00 (0.00%) | 29.82 - 51.40 | 11.0 thousand (Below Avg) |
Market data as of 4:04PM 05/22/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 49.72 |
| Day's Range | -- - -- |
| Market Cap | 7.1B |
| Avg Volume (10 Day) | 742.6K |
| Price/Earnings (Trailing 12 Mo.) | 23.3x |
| Earnings Per Share (Trailing 12 Mo.) | 2.13 |
| Dividend Yield | 0.17 (1.37%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Pass |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
ResMed Inc. Announces Record Financial Results For The Quarter Ended And Nine Months Ended March 31, 2013
PR Newswire - Thursday 04/25/2013 4:05 PM ET
ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
PR Newswire - Thursday 04/25/2013 8:00 AM ET
| RMD | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 9.96% | |
| Net Income Growth (1yr) | -1.46% | |
| Total Debt/Equity | 0.19 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 4.29% | |
| Price/Sales | 4.81 |
| Company | Last | Change |
|---|---|---|
| Edwards Lifesciences Corp | 64.30 | 0.00% |
| Varian Medical Systems Inc | 68.43 | 0.00% |
| Hologic Inc | 20.46 | 0.00% |
| Sirona Dental Systems Inc | 69.40 | 0.00% |
| Smith & Nephew PLC | 59.26 | 0.00% |
Data is delayed by at least 15 min.